{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:38:10Z","timestamp":1793111890141,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Bacterial infection remains as one of the major healthcare issues, despite significant scientific and medical progress in this field. Infection by <jats:italic>Streptococcus Pneumoniae<\/jats:italic> (<jats:italic>S. Pneumoniae<\/jats:italic>) can cause pneumonia and other serious infectious diseases, such as bacteremia, sinusitis and meningitis. The pneumococcal capsular polysaccharides (CPS) that constitute the outermost layer of the bacterial cell are the main immunogens and protect the pathogen from host defense mechanisms. Over 90 pneumococcal CPS serotypes have been identified, among which more than 30 can cause invasive pneumococcal diseases that could lead to morbidity and mortality. Multivalent pneumococcal vaccines have been developed to prevent diseases caused by <jats:italic>S. Pneumoniae<\/jats:italic>. These vaccines employ either purified pneumococcal CPSs or protein conjugates of these CPSs to generate antigen-specific immune responses for patient protection. Serotype-specific quantitation of these polysaccharides (Ps) antigen species are required for vaccine clinical dosage, product release and quality control. Herein, we have developed an antibody-enhanced high-performance liquid chromatography (HPLC) assay for serotype-specific quantitation of the polysaccharide contents in multivalent pneumococcal conjugate vaccines (PCVs). A fluorescence-labeled multiplex assay format has also been developed. This work laid the foundation for a serotype-specific antigen assay format that could play an important role for future vaccine research and development.<\/jats:p>","DOI":"10.1038\/s41541-022-00584-9","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T16:03:52Z","timestamp":1674489832000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Antibody enhanced HPLC for serotype-specific quantitation of polysaccharides in pneumococcal conjugate vaccine"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6599-7716","authenticated-orcid":false,"given":"James Z.","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Kuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9833-0483","authenticated-orcid":false,"given":"Ashley","family":"Drumheller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxiang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Ansbro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milica","family":"Grozdanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachelle","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,23]]},"reference":[{"key":"584_CR1","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1128\/CMR.00024-15","volume":"28","author":"KA Geno","year":"2015","unstructured":"Geno, K. A. et al. Pneumococcal capsules and their types: past, present, and future. Clin. Microbiol. Rev. 28, 871\u2013899 (2015).","journal-title":"Clin. Microbiol. Rev."},{"key":"584_CR2","first-page":"27","volume":"21","author":"CC Daniels","year":"2016","unstructured":"Daniels, C. C., Rogers, P. D. & Shelton, C. M. A review of pneumococcal vaccines: current polysaccharide vaccine recommendations and future protein antigens. J. Pediatr. Pharm. Ther. 21, 27\u201335 (2016).","journal-title":"J. Pediatr. Pharm. Ther."},{"key":"584_CR3","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/infdis\/154.2.245","volume":"154","author":"DM Musher","year":"1986","unstructured":"Musher, D. M. et al. Natural and vaccine-related immunity to Streptococcus pneumoniae. J. Infect. Dis. 154, 245\u2013256 (1986).","journal-title":"J. Infect. Dis."},{"key":"584_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.it.2004.11.004","volume":"26","author":"S Weller","year":"2005","unstructured":"Weller, S., Reynaud, C. A. & Weill, J. C. Vaccination against encapsulated bacteria in humans: paradoxes. Trends Immunol. 26, 85\u201389 (2005).","journal-title":"Trends Immunol."},{"key":"584_CR5","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1001\/jama.1993.03510150060030","volume":"270","author":"JC Butler","year":"1993","unstructured":"Butler, J. C. et al. Pneumococcal polysaccharide vaccine efficacy: an evaluation of current recommendations. J. Am. Med. Assoc. 270, 1826\u20131831 (1993).","journal-title":"J. Am. Med. Assoc."},{"key":"584_CR6","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1080\/14760584.2021.1880328","volume":"20","author":"MS Niedermana","year":"2021","unstructured":"Niedermana, M. S. et al. Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence. Expert Rev. Vaccines 20, 243\u2013256 (2021).","journal-title":"Expert Rev. Vaccines"},{"key":"584_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1749-6632.2012.06673.x","volume":"1263","author":"WC Gruber","year":"2012","unstructured":"Gruber, W. C., Scott, D. A. & Emini, E. Development and clinical evaluation of Prevnar 13, a 13-valent pneumococcal CRM197 conjugate vaccine. Ann. NY Acad. Sci. 1263, 15\u201326 (2012).","journal-title":"Ann. NY Acad. Sci."},{"key":"584_CR8","doi-asserted-by":"publisher","first-page":"7494","DOI":"10.1016\/j.vaccine.2021.10.032","volume":"39","author":"K Cannon","year":"2021","unstructured":"Cannon, K. et al. A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults \u226565 years of age with different prior pneumococcal vaccination. Vaccine 39, 7494\u20137502 (2021).","journal-title":"Vaccine"},{"key":"584_CR9","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1586\/erv.09.113","volume":"8","author":"R Prymula","year":"2009","unstructured":"Prymula, R. & Schuerman, L. 10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: synflorix. Expert Rev. Vaccines 8, 1479\u20131500 (2009).","journal-title":"Expert Rev. Vaccines"},{"key":"584_CR10","doi-asserted-by":"publisher","first-page":"6883","DOI":"10.1016\/j.vaccine.2018.02.113","volume":"36","author":"D Greenberg","year":"2018","unstructured":"Greenberg, D. et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants. Vaccine 36, 6883\u20136891 (2018).","journal-title":"Vaccine"},{"key":"584_CR11","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.vaccine.2021.08.049","volume":"40","author":"HL Platt","year":"2022","unstructured":"Platt, H. L. et al. A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE). Vaccine 40, 162\u2013172 (2022).","journal-title":"Vaccine"},{"key":"584_CR12","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1080\/21645515.2018.1532250","volume":"15","author":"JT Peterson","year":"2019","unstructured":"Peterson, J. T. et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults \u226565 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Hum. Vaccin Immunother. 15, 540\u2013548 (2019).","journal-title":"Hum. Vaccin Immunother."},{"key":"584_CR13","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1001\/jama.294.16.2043","volume":"294","author":"CA Lexau","year":"2005","unstructured":"Lexau, C. A. et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. J. Am. Med. Assoc. 294, 2043\u20132051 (2005).","journal-title":"J. Am. Med. Assoc."},{"key":"584_CR14","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.1016\/j.ijid.2009.05.010","volume":"14","author":"DJ Isaacman","year":"2010","unstructured":"Isaacman, D. J., McIntosh, E. D. & Reinert, R. R. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J. Infect. Dis. 14, e197\u2013e209 (2010).","journal-title":"Int J. Infect. Dis."},{"key":"584_CR15","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3390\/vaccines8010132","volume":"8","author":"M Masomian","year":"2020","unstructured":"Masomian, M., Ahmad, Z., Gew, L. T. & Poh, C. L. Development of next generation Streptococcus pneumonia vaccines conferring broad protection. Vaccines 8, 132 (2020).","journal-title":"Vaccines"},{"key":"584_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-00232-0","volume":"5","author":"JT Poolman","year":"2020","unstructured":"Poolman, J. T. Expanding the role of bacterial vaccines into life-course vaccination strategies and prevention of antimicrobial-resistant infections. npj Vaccines 5, 84 (2020).","journal-title":"npj Vaccines"},{"key":"584_CR17","doi-asserted-by":"publisher","first-page":"6468","DOI":"10.1016\/j.vaccine.2009.06.013","volume":"27","author":"CE Frasch","year":"2009","unstructured":"Frasch, C. E. Preparation of bacterial polysaccharide\u2013protein conjugates: analytical and manufacturing challenges. Vaccine 27, 6468\u20136470 (2009).","journal-title":"Vaccine"},{"key":"584_CR18","doi-asserted-by":"publisher","first-page":"eabe9444","DOI":"10.1126\/sciadv.abe9444","volume":"7","author":"JC Stark","year":"2021","unstructured":"Stark, J. C. et al. On-demand biomanufacturing of protective conjugate vaccines. Sci. Adv. 7, eabe9444 (2021).","journal-title":"Sci. Adv."},{"key":"584_CR19","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/B978-0-12-820954-7.00008-6","volume":"2","author":"R Biemans","year":"2020","unstructured":"Biemans, R., Micoli, F. & Romano, M. R. Glycoconjugate vaccines, production and characterization. Recent Trends Carbohydr. Chem. 2, 285\u2013313 (2020).","journal-title":"Recent Trends Carbohydr. Chem."},{"key":"584_CR20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.4155\/bio-2017-0176","volume":"10","author":"T Verch","year":"2018","unstructured":"Verch, T., Trausch, J. J. & Shank-Retzlaff, M. Principles of vaccine potency assays. Bioanalysis 10, 163\u2013180 (2018).","journal-title":"Bioanalysis"},{"key":"584_CR21","doi-asserted-by":"publisher","first-page":"5913","DOI":"10.1016\/j.vaccine.2015.07.104","volume":"33","author":"AP Manceur","year":"2015","unstructured":"Manceur, A. P. & Kamen, A. A. Critical review of current and emerging quantification methods for the development of influenza vaccine candidates. Vaccine 33, 5913\u20135919 (2015).","journal-title":"Vaccine"},{"key":"584_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-018-0080-6","volume":"3","author":"RT Byrne-Nash","year":"2018","unstructured":"Byrne-Nash, R. T. et al. VaxArray potency assay for rapid assessment of \u201cpandemic\u201d influenza vaccines. npj Vaccines 3, 1\u201311 (2018).","journal-title":"npj Vaccines"},{"key":"584_CR23","doi-asserted-by":"publisher","first-page":"7815","DOI":"10.1016\/j.vaccine.2020.10.017","volume":"38","author":"S Phugare","year":"2020","unstructured":"Phugare, S. et al. Quantitation of novel pentavalent meningococcal polysaccharide conjugate vaccine (Men A-TT, Men C-CRM, Men Y-CRM, Men W-CRM, Men X-TT) using sandwich ELISA. Vaccine 38, 7815\u20137824 (2020).","journal-title":"Vaccine"},{"key":"584_CR24","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3390\/vaccines9020100","volume":"9","author":"JH Gillis","year":"2021","unstructured":"Gillis, J. H. et al. Multiplexed VaxArray immunoassay for rapid antigen quantification in measles and rubella vaccine manufacturing. Vaccine 9, 100\u2013113 (2021).","journal-title":"Vaccine"},{"key":"584_CR25","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1006\/biol.2001.0320","volume":"30","author":"C Lee","year":"2002","unstructured":"Lee, C. Quality control of polyvalent pneumococcal polysaccharide-protein conjugate vaccine by nephelometry. Biologicals 30, 97\u2013103 (2002).","journal-title":"Biologicals"},{"key":"584_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00317-4","volume":"6","author":"G Sanyal","year":"2021","unstructured":"Sanyal, G., S\u00e4rnef\u00e4lt, A. & Kumar, A. Considerations for bioanalytical characterization and batch release of COVID-19 vaccines. npj Vaccines 6, 53 (2021).","journal-title":"npj Vaccines"},{"key":"584_CR27","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2022.013","author":"JZ Deng","year":"2022","unstructured":"Deng, J. Z. et al. RP-UPLC method for oncolytic coxsackievirus viral protein separation and empty to full capsid quantification. Hum. Gene Ther. https:\/\/doi.org\/10.1089\/hum.2022.013 (2022).","journal-title":"Hum. Gene Ther."},{"key":"584_CR28","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S0731-7085(99)00183-1","volume":"21","author":"QP Lei","year":"2000","unstructured":"Lei, Q. P., Lamb, D. H., Heller, R. & Pietrobon, P. Quantitation of low level unconjugated polysaccharide in tetanus toxoid-conjugate vaccine by HPAEC\/PAD following rapid separation by deoxycholate\/HCl. J. Pharm. Biomed. Anal. 21, 1087\u20131091 (2000).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"584_CR29","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.4161\/hv.29696","volume":"10","author":"F Gao","year":"2014","unstructured":"Gao, F., Lockyer, K., Burkin, K., Crane, D. T. & Bolgiano, B. A physico-chemical assessment of the thermal stability of pneumococcal conjugate vaccine components. Hum. Vaccines Immunotherapeutics 10, 2744 (2014).","journal-title":"Hum. Vaccines Immunotherapeutics"},{"key":"584_CR30","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.carbpol.2016.06.095","volume":"152","author":"M Hadidi","year":"2016","unstructured":"Hadidi, M., Buckley, J. J. & Zydney, A. L. Effects of solution conditions on characteristics and size exclusion chromatography of pneumococcal polysaccharides and conjugate vaccines. Carbohydr. Polym. 152, 12\u201318 (2016).","journal-title":"Carbohydr. Polym."},{"key":"584_CR31","doi-asserted-by":"crossref","unstructured":"Abdelhameed, A. S. et al. Solution conformation and flexibility of capsular polysaccharides from Neisseria meningitidis and glycoconjugates with the tetanus toxoid protein. Sci. Rep. 6, 35588 (2016).","DOI":"10.1038\/srep35588"},{"key":"584_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00409-1","volume":"6","author":"C Anish","year":"2021","unstructured":"Anish, C., Beurret, M. & Poolman, J. Combined effects of glycan chain length and linkage type on the immunogenicity of glycoconjugate vaccines. npj Vaccines 6, 150 (2021).","journal-title":"npj Vaccines"},{"key":"584_CR33","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1084\/jem.169.6.2121","volume":"169","author":"MR Wessels","year":"1989","unstructured":"Wessels, M. R. & Kasper, D. L. Antibody recognition of the type 14 pneumococcal capsule: evidence for a conformational epitope in a neutral polysaccharide. J. Exp. Med. 169, 2121\u20132131 (1989).","journal-title":"J. Exp. Med."},{"key":"584_CR34","doi-asserted-by":"crossref","unstructured":"Zou, W & Jennings, H. J. The conformational epitope of type III group B streptococcus capsular polysaccharide. Adv. Exp. Med. Biol. 491, 473\u2013484 (2001).","DOI":"10.1007\/978-1-4615-1267-7_31"},{"key":"584_CR35","doi-asserted-by":"publisher","first-page":"9976","DOI":"10.1073\/pnas.0801711105","volume":"105","author":"B Vulliez-Le Normand","year":"2008","unstructured":"Vulliez-Le Normand, B. et al. Structures of synthetic O-antigen fragments from serotype 2a Shigella flexneri in complex with a protective monoclonal antibody. PNAS USA 105, 9976\u20139981 (2008).","journal-title":"PNAS USA"},{"key":"584_CR36","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.sbi.2019.12.001","volume":"62","author":"C Soliman","year":"2020","unstructured":"Soliman, C., Pier, G. B. & Ramsland, P. A. Antibody recognition of bacterial surfaces and extracellular polysaccharides. Curr. Opin. Struct. Biol. 62, 48\u201355 (2020).","journal-title":"Curr. Opin. Struct. Biol."},{"key":"584_CR37","doi-asserted-by":"publisher","first-page":"29795","DOI":"10.1073\/pnas.2011385117","volume":"117","author":"P Henriques","year":"2020","unstructured":"Henriques, P. et al. Structure of a protective epitope reveals the importance of acetylation of Neisseria meningitidis serogroup A capsular polysaccharide. PNAS USA 117, 29795\u201329802 (2020).","journal-title":"PNAS USA"},{"key":"584_CR38","first-page":"139","volume":"24","author":"JZ Deng","year":"2022","unstructured":"Deng, J. Z. et al. SEC coupled with in-line multiple detectors for the characterization of an oncolytic coxsackievirus. Mol. Ther.: Oncolytics 24, 139\u2013147 (2022).","journal-title":"Mol. Ther.: Oncolytics"},{"key":"584_CR39","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/j.vaccine.2022.01.042","volume":"40","author":"JZ Deng","year":"2022","unstructured":"Deng, J. Z. et al. Multi-attribute characterization of pneumococcal conjugate vaccine by size-exclusion chromatography coupled with UV-MALS-RI detections. Vaccine 40, 1464\u20131471 (2022).","journal-title":"Vaccine"},{"key":"584_CR40","doi-asserted-by":"publisher","first-page":"3769","DOI":"10.3390\/polym14183769","volume":"14","author":"JZ Deng","year":"2022","unstructured":"Deng, J. Z., Lin, J., Chen, M., Lancaster, C. & Zhuang, P. Characterization of high molecular weight pneumococcal conjugate by SEC-MALS and AF4-MALS. Polymers 14, 3769 (2022).","journal-title":"Polymers"},{"key":"584_CR41","unstructured":"International Conference on Harmonisation. Validation of Analytical Procedures: Text And Methodology Q2 (R1). (International Conference on Harmonisation, 2005)."},{"key":"584_CR42","unstructured":"Center for Drug Evaluation and Research (CDER) and Center for Veterinary Medicine (CVM). Food and Drug Administration Bioanalytical Method Validation: Guidance for Industry https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf (2018)."},{"key":"584_CR43","doi-asserted-by":"publisher","first-page":"4231","DOI":"10.1016\/j.vaccine.2021.04.067","volume":"39","author":"D McGuinness","year":"2021","unstructured":"McGuinness, D. et al. Immunogenicity of PCV24, an expanded pneumococcal conjugate vaccine, in adult monkeys and protection in mice. Vaccine 39, 4231\u20134237 (2021).","journal-title":"Vaccine"},{"key":"584_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3517-7","volume":"18","author":"Z Chen","year":"2018","unstructured":"Chen, Z. et al. Human monoclonal antibodies isolated from a primary pneumococcal conjugate vaccine demonstrates the expansion of an antigen-driven hypermutated memory B cell response. BMC Infect. Dis. 18, 613 (2018).","journal-title":"BMC Infect. Dis."},{"key":"584_CR45","doi-asserted-by":"publisher","first-page":"180","DOI":"10.4049\/jimmunol.200.Supp.180.27","volume":"200","author":"KS Cox","year":"2018","unstructured":"Cox, K. S. et al. Efficient isolation of monoclonal antibodies from antigen-specific human plasmablasts and memory B cells from a pneumococcal conjugate vaccine. J. Immunol. 200, 180 (2018).","journal-title":"J. Immunol."},{"key":"584_CR46","unstructured":"Ahl, P. L. et al. Methods for producing Streptococcus pneumoniae capsular polysaccharide carrier protein conjugates. Patent application US20210252125A1."},{"key":"584_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0003-2670(93)80373-S","volume":"272","author":"PJ Wyatt","year":"1993","unstructured":"Wyatt, P. J. Light scattering and the absolute characterization of macromolecules. Anal. Chim. Acta 272, 1\u201340 (1993).","journal-title":"Anal. Chim. Acta"},{"key":"584_CR48","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1063\/1.1746738","volume":"16","author":"BH Zimm","year":"1948","unstructured":"Zimm, B. H. The scattering of light and the radial distribution function of high polymer solutions. J. Chem. Phys. 16, 1093\u20131099 (1948).","journal-title":"J. Chem. Phys."},{"key":"584_CR49","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1006\/abio.2001.5411","volume":"299","author":"BS Kendrick","year":"2001","unstructured":"Kendrick, B. S., Kerwin, B. A., Chang, B. S. & Philo, J. S. Online size-exclusion high-performance liquid chromatography light scattering and differential refractometry methods to determine degree of polymer conjugation to proteins and protein-protein or protein-ligand association states. Anal. Biochem. 299, 136\u2013146 (2001).","journal-title":"Anal. Biochem."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00584-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00584-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00584-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T17:04:08Z","timestamp":1674493448000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00584-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,23]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["584"],"URL":"https:\/\/doi.org\/10.1038\/s41541-022-00584-9","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,23]]},"assertion":[{"value":"21 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors are current employees of Merck & Co., Inc., Rahway, NJ, USA, and may hold stocks or stock options of this company. The authors declare that none of the authors has competing financial interests that can affect the data collection and data interpretation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}